Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea
Status:
Completed
Trial end date:
2012-10-31
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg
twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive
(HIV+) subjects with diarrhea.
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.